Compare Ginkgo Bioworks Holdings Inc (DNA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs GeneDx Holdings Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.6× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and GeneDx Holdings Corp for 19 Days on average.
| DNA | WGS | |
|---|---|---|
Market Cap | $763.64M | $2.02B |
Volume | 3,204,177 | 734,640 |
Sector | Health | Health |
52-Week High | $15.83 | $167.51 |
52-Week Low | $5.48 | $34.51 |
Typical Hold Time | 7 Days | 19 Days |
Enterprise Value | $865.59M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with a negative net income margin of -219.6%. Recent news includes a partnership with TuneLab and a $17.5 million ARPA-H subcontract.
The outlook is challenged by persistent losses and negative cash flow, though strategic partnerships offer growth potential. Analyst sentiment is divided evenly between buy, hold, and sell ratings. Key risks include execution on profitability and high cash burn. The stock presents a speculative opportunity dependent on the company's ability to monetize its technology platform.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
